| ［1］ |
Tavakolpour S, Mahmoudi H, Balighi K, et al. Sixteen⁃year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review［J］. Int Immunopharmacol, 2018（54）:131⁃138.doi: 10.1016/j.intimp.2017.11.005 .
|
| ［2］ |
徐凯峰, 田欣伦. 呼吸与危重症医学专科医师培训精要［M］. 北京: 人民卫生出版社, 2020:282⁃283.
|
| ［3］ |
Kolstad A, Holte H, Fosså A, et al. Pneumocystis jirovecii pneumonia in B⁃cell lymphoma patients treated with the rituximab⁃CHOEP⁃14 regimen［J］. Haematologica, 2007,92（1）:139⁃140. doi: 10.3324/haematol.10564 .
|
| ［4］ |
Sharma V K, Gupta V, Bhari N , et al. Rituximab as an adjuvant therapy for pemphigus: experience in 61 patients from a single center with long⁃term follow⁃up［J］. Int J Dermatol, 2020,59（1）: 76⁃81. doi: 10.1111/ijd.14546.
|
| ［5］ |
Amber KT, Lamberts A, Solimani F, et al. Determining the incidence of Pneumocystis pneumonia in patients with autoimmune blistering diseases not receiving routine prophylaxis［J］. JAMA Dermatol, 2017,153（11）:1137⁃1141. doi:10.1001/jamadermatol.2017.2808.
|
| ［6］ |
Wei KC, Wang YH, Wang WH, et al. Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab［J］. J Eur Acad Dermatol Venereol, 2017,31（8）:e350⁃e351. doi:10.1111/jdv.14144 .
|
| ［7］ |
Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti⁃CD20 antibody（rituximab）［J］. J Am Acad Dermatol, 2004,51（5）:817⁃819. doi:10.1016/j.jaad.2004.06.007.
|
| ［8］ |
Shimanovich I, Nitschke M, Rose C, et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins［J］. Br J Dermatol, 2008,158（2）:382⁃388. doi: 10.1111/j.1365⁃2133.2007.08358.x .
|
| ［9］ |
Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non⁃HIV⁃infected patients: systematic review and meta⁃analysis of randomized controlled trials［J］. Mayo Clin Proc, 2007,82（9）:1052⁃1059. doi: 10.4065/82.9.1052.
|
